Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to fight Obesity-Linked inflammation

NCT ID NCT07656727

Disease control Sponsor: BioAge Labs, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study tests an experimental drug called BGE-102 in 160 adults with obesity and heart risk factors. The goal is to see if it lowers inflammation (measured by hsCRP) safely. Participants take either BGE-102 or a placebo daily for 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BGE-102 (oral drug)
What this could lead to
If it works, this could point toward a new way to reduce inflammation and improve heart health in people with obesity.
What could go wrong
This is an early Phase 2 trial with only 160 people over 12 weeks. It may not show meaningful benefits or could have side effects. Success is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Obese Male and Female adults with BMI 32-42 kg/m² * Elevated blood test for hsCRP consistent with chronic systemic inflammation * At least one cardiovascular risk factor or metabolic syndrome feature * Stable background therapies and willing to maintain stable diet/exercise habits during the study Key Exclusion Criteria: * Type 1 diabetes, * Uncontrolled Type 2 diabetes, * Uncontrolled hypertension and /or hyperlipidemia * Recent weight change of 5% or more, * Use of weight-loss medications/programs * Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult. * Clinically significant ECG abnormalities or arrhythmias * Use of prohibited medications (including GLP-1 therapies, immunosuppressants, chronic anti-inflammatory drugs, or moderate or strong CYP3A4 modulators) * Contraindications to MRI * Clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass \[bariatric\] surgery or restrictive bariatric surgery), or have an endoscopic and/or device-based therapy for obesity * Women who are pregnant or nursing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity and cardiovascular risk

Contacts and locations

Locations

  • Site 100

    Rogers, Arkansas, 72758, United States

  • Site 101

    San Antonio, Texas, 78240, United States

  • Site 102

    Miami, Florida, 33172, United States

  • Site 103

    Lexington, Kentucky, 40509, United States

  • Site 104

    Port Orange, Florida, 32127, United States

  • Site 105

    San Juan, 00927, Puerto Rico

  • Site 106

    Rockville, Maryland, 20854, United States

  • Site 108

    Chandler, Arizona, 85225, United States

  • Site 109

    Maitland, Florida, 32751, United States

  • Site 110

    Tucson, Arizona, 85711, United States

  • Site 111

    Hartsdale, New York, 10530, United States

  • Site 112

    Austin, Texas, 78759, United States

  • Site 113

    Kansas City, Missouri, 64131, United States

  • Site 114

    Dallas, Texas, 75230, United States

  • Site 115

    Peoria, Arizona, 85381, United States

  • Site 116

    Las Vegas, Nevada, 89109, United States

  • Site 117

    Sugar Land, Texas, 77478, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.